These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 11844900

  • 1. Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation.
    Hwang WJ, Yao WJ, Wey SP, Shen LH, Ting G.
    Eur Neurol; 2002; 47(2):113-7. PubMed ID: 11844900
    [Abstract] [Full Text] [Related]

  • 2. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
    Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W.
    Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
    [Abstract] [Full Text] [Related]

  • 3. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
    Pizzolato G, Chierichetti F, Rossato A, Cagnin A, Fabbri M, Dam M, Ferlin G, Battistin L.
    J Neural Transm Suppl; 1995 May; 45():113-22. PubMed ID: 8748616
    [Abstract] [Full Text] [Related]

  • 4. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL.
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [Abstract] [Full Text] [Related]

  • 5. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
    Hierholzer J, Cordes M, Schelosky L, Barzen G, Poewe W, Henkes H, Keske U, Horowski R, Felix R.
    Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
    [Abstract] [Full Text] [Related]

  • 6. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W, Grundmann M, Huber G.
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
    Verstappen CC, Bloem BR, Haaxma CA, Oyen WJ, Horstink MW.
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905
    [Abstract] [Full Text] [Related]

  • 10. [18F]fallypride characterization of striatal and extrastriatal D2/3 receptors in Parkinson's disease.
    Stark AJ, Smith CT, Petersen KJ, Trujillo P, van Wouwe NC, Donahue MJ, Kessler RM, Deutch AY, Zald DH, Claassen DO.
    Neuroimage Clin; 2018 Apr; 18():433-442. PubMed ID: 29541577
    [Abstract] [Full Text] [Related]

  • 11. Dopamine receptor SPET imaging in Parkinson's disease: a [123I]-IBZM and [99mTc]-HM-PAO study.
    Pizzolato G, Chierichetti F, Rossato A, Briani C, Dam M, Borsato N, Saitta B, Zanco P, Ferlin G, Battistin L.
    Eur Neurol; 1993 Apr; 33(2):143-8. PubMed ID: 8467821
    [Abstract] [Full Text] [Related]

  • 12. Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
    Dentresangle C, Veyre L, Le Bars D, Pierre C, Lavenne F, Pollak P, Guerin J, Froment JC, Brousolle E.
    Mov Disord; 1999 Nov; 14(6):1025-30. PubMed ID: 10584682
    [No Abstract] [Full Text] [Related]

  • 13. Cerebral uptake and utilization of therapeutic [beta-11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response.
    Tedroff J, Aquilonius SM, Hartvig P, Bredberg E, Bjurling P, Långström B.
    Acta Neurol Scand; 1992 Feb; 85(2):95-102. PubMed ID: 1574995
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J, Cordes M, Venz S, Schelosky L, Harisch C, Richter W, Keske U, Hosten N, Mäurer J, Poewe W, Felix R.
    J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
    Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel WH.
    Mov Disord; 1997 Nov; 12(6):898-902. PubMed ID: 9399212
    [Abstract] [Full Text] [Related]

  • 19. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
    Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ, REAL-PET Study Group.
    Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
    [Abstract] [Full Text] [Related]

  • 20. A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.
    Tibbo P, Silverstone PH, McEwan AJ, Scott J, Joshua A, Golberg K.
    J Psychiatry Neurosci; 1997 Jan; 22(1):39-45. PubMed ID: 9002391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.